Table 3.
Relationship between CD24 expression and HIF-1α or HIF-2α in gastric cancer
| CD24 (–) n (%) | CD24 (+) n (%) | P-value | |
|---|---|---|---|
| All cases (n = 119) | |||
| HIF-1α | |||
| (–) | 54 (57.4%) | 40 (42.6%) | <0.001 |
| (+) | 4 (16.0%) | 21 (84.0%) | |
| HIF-2α | |||
| (–) | 45 (60.8%) | 29 (39.2%) | 0.002 |
| (+) | 13 (28.9%) | 32 (71.1%) | |
| Diffuse type (n = 61) | |||
| HIF-1α | |||
| (–) | 32 (68.1%) | 15 (31.9%) | 0.002 |
| (+) | 3 (21.4%) | 11 (78.6%) | |
| HIF-2α | |||
| (–) | 24 (68.6%) | 11 (31.4%) | 0.040 |
| (+) | 11 (42.3%) | 15 (57.7%) | |
| Intestinal type (n = 58) | |||
| HIF-1α | |||
| (–) | 22 (46.8%) | 25 (53.2%) | 0.021 |
| (+) | 1 (9.1%) | 10 (90.9%) | |
| HIF-2α | |||
| (–) | 21 (53.8%) | 18 (46.2%) | 0.001 |
| (+) | 2 (10.5%) | 17 (89.5%) | |